Skip to main content

Table 3 Maximum annual cost of intervention (over 10 years) per patient to be cost-effective at various cost-effectiveness thresholds

From: Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia

Willing-to-pay threshold

% of potential improvement attained during first 12 months of treatment

55%

65%

75% (Base case)

85%

95%

20,000

4,254

5,000

5,742

6,481

7,218

30,000

6,382

7,499

8,613

9,722

10,827

40,000

8,509

9,999

11,484

12,963

14,436

50,000

10,636

12,499

14,355

16,203

18,045

60,000

12,763

14,999

17,226

19,444

21,653

70,000

14,890

17,498

20,097

22,685

25,262

80,000

17,017

19,998

22,967

25,925

28,871

90,000

19,145

22,498

25,838

29,166

32,480

100,000

21,272

24,998

28,709

32,406

36,089